Author:
Liu Fang,Lee Seul A.,Riordan Stephen M.,Zhang Li,Zhu Lixin
Abstract
Inflammatory bowel disease (IBD) is a chronic inflammatory condition of the gastrointestinal tract mainly comprising two forms including Crohn's disease (CD) and ulcerative colitis (UC). IBD is a lifelong relapsing remitting disease and relapses occur at random patterns which are unpredictable. Fecal biomarkers have been increasingly used to assess disease activity in IBD due to their positive correlations with intestinal inflammation. Recent studies have also assessed the use of fecal biomarkers in predicting relapse and post-operative recurrence. This review provides information from global studies of using fecal calprotectin, lactoferrin and S100A12 to predict relapse in IBD. Strategies for further studies and the use of these fecal biomarkers for personalized management in IBD are also discussed.
Funder
National Natural Science Foundation of China
Reference100 articles.
1. Disease monitoring in inflammatory bowel disease;Chang;World J Gastroenterol,2015
2. Fecal biomarkers in inflammatory bowel disease;Lopez;J Gastroenterol Hepatol,2017
3. Normalization of faecal calprotectin: a predictor of mucosal healing in patients with inflammatory bowel disease;Røseth;Scand J Gastroenterol,2004
4. Fecal calprotectin, lactoferrin, and endoscopic disease activity in monitoring anti-TNF-alpha therapy for Crohn's disease;Sipponen;Inflamm Bowel Dis,2008
5. Noninvasive markers in the assessment of intestinal inflammation in inflammatory bowel diseases: performance of fecal lactoferrin, calprotectin, and PMN-elastase, CRP, and clinical indices;Langhorst;Am J Gastroenterol,2008
Cited by
22 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献